再生元制药公司宣布,Libtayo获批新用药方案:在初始12周每3周给予350毫克之后,可改为每6周给药700毫克。
再生元制药公司宣布,Libtayo获批新用药方案:在初始12周每3周给予350毫克之后,可改为每6周给药700毫克。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.